1. Home
  2. TENX vs IXHL Comparison

TENX vs IXHL Comparison

Compare TENX & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$11.75

Market Cap

56.2M

Sector

Health Care

ML Signal

HOLD

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$4.68

Market Cap

45.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
IXHL
Founded
1967
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
45.0M
IPO Year
2001
2024

Fundamental Metrics

Financial Performance
Metric
TENX
IXHL
Price
$11.75
$4.68
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
605.5K
430.8K
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.34
$0.16
52 Week High
$18.38
$6.39

Technical Indicators

Market Signals
Indicator
TENX
IXHL
Relative Strength Index (RSI) 37.17 66.67
Support Level $10.83 $0.34
Resistance Level $14.15 $5.17
Average True Range (ATR) 0.95 0.36
MACD -0.28 0.05
Stochastic Oscillator 7.00 78.83

Price Performance

Historical Comparison
TENX
IXHL

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: